Share This Article:

Prevalence of Nsaids (Non Steroidal Inflammatory Drugs) as a Chemopreventive Agent in Different Types of Cancer: Retrospective Detail Studies

DOI: 10.4236/oalib.1101830    813 Downloads   1,117 Views  


NSAIDs are the most widely used drugs globaly and are very famous for their analgesic, anti-in-flammatory and antipyretic actions. The use of NSAIDs in a variety of cancerous conditions is also approved now because of its versatile pharmacologic actions. In this research based study the use of NSAIDs as a chemointerceptive agent in a variety of cancers has been discussed. We aimed to know about the chemopreventive effects of NSAIDs that are a very diverse group of drugs having a lot of pharmacological actions. Now they are advised to prevent from various types of cancers by its different mechanisms and processes like inhibition of angiogenesis, COX-2 and it potentiates the process of apoptosis which is also a very favourable point for NSAIDs to work as a chemointerceptive agent. Heeding to the results aspirin could intercept from cancer (37%) and other NSAIDs used as acheminterceptive agents (28%). All of the NSAIDs have less side effects as compared to the drugs that are used during chemotherapy. The inhibition of COX-1 enzyme by NSAIDs is (15%) and that of COX-2 (85%). Studies suggested that the most frequent cancer in males is 14.5% of colorectal cancer and 10% prostate cancer while in female the most common cancers are 27% of breast cancer and 15% of colorectal cancer. 30% of ovarian cancer is also very common in many females of elder age groups. It was concluded that NSAIDs are a diverse group of drugs and advised to manipulate as a chemointerceptive agents in a variety of cancers. Besides these studies there are many limitations heeding to the chronic usage of NSAIDs, which should also be considered. The use of NSAIDs as a chemointerceptive agent requires more further experimental studies and needs clinical trials.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Ayub, M. and Islam, A. (2015) Prevalence of Nsaids (Non Steroidal Inflammatory Drugs) as a Chemopreventive Agent in Different Types of Cancer: Retrospective Detail Studies. Open Access Library Journal, 2, 1-11. doi: 10.4236/oalib.1101830.


[1] GLOBOCAN 2012 v1.0 (2013) Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [database on the Internet]. International Agency for Research on Cancer.
[2] Siegel, R., Ma, J., Zou, Z., et al. (2014) Cancer Statistics. CA: A Cancer Journal for Clinicians, 64, 9-29.
[3] Pohl, H. and Welch, H.G. (2005) The Role of Overdiagnosis and Reclassification in the Marked Increase of Esophageal Adenocarcinoma Incidence. Journal of the National Cancer Institute, 97, 142-146.
[4] Pohl, H., Sirovich, B. and Welch, H.G. (2010) Esophageal Adenocarcinoma Incidence: Are We Reaching the Peak? Cancer Epidemiology, Biomarkers & Prevention, 19, 1468-1470.
[5] Thrift, A.P. and Whiteman, D.C. (2012) The Incidence of Esophageal Adenocarcinoma Continues to Rise: Analysis of Period and Birth Cohort Effects on Recent Trends. Annals of Oncology, 23, 3155-3162.
[6] Vaughan, T.L. and Fitzgerald, R.C. (2015) Precision Prevention of Oesophageal Adenocarcinoma. Nature Reviews Gastroenterology & Hepatology, 12, 243-248.
[7] Engel, L.S., Chow, W.-H., Vaughan, T.L., et al. (2003) Population Attributable Risks of Esophageal and Gastric Cancers. Journal of the National Cancer Institute, 95, 1404-1413.
[8] Pandeya, N., Olsen, C.M. and Whiteman, D.C. (2013) Sex Differences in the Proportion of Esophageal Squamous Cell Carcinoma Cases Attributable to Tobacco Smoking and Alcohol Consumption. Cancer Epidemiology, 37, 579-584.
[9] Howlader, N., Noone, A., Krapcho, M., et al. (2014) SEER Cancer Statistics Review, 1975-2011. National Cancer Institute. Bethesda, MD. (Based on November 2013 SEER data submission, posted to the SEER web site, April 2014)
[10] Cook, M.B., Chow, W.H. and Devesa, S.S. (2009) Oesophageal Cancer Incidence in the United States by Race, Sex, and Histologic Type, 1977-2005. British Journal of Cancer, 101, 855-859.
[11] Dubecz, A., Gall, I., Solymosi, N., Schweigert, M., Peters, J.H., Feith, M. and Stein, H.J. (2012) Temporal Trends in Long-Term Survival and Cure Rates in Esophageal Cancer: A SEER Database Analysis. Journal of Thoracic Oncology, 7, 443-447.
[12] Spechler, S.J. (2002) Clinical Practice. Barrett’s Esophagus. The New England Journal of Medicine, 346, 836-842.
[13] Ronkainen, J., Aro, P., Storskrubb, T., Johansson, S.E., Lind, T., Bolling-Sternevald, E., et al. (2005) Prevalence of Barrett’s Esophagus in the General Population: An Endoscopic Study. Gastroenterology, 129, 1825-1831.
[14] Kendall, B.J. and Whiteman, D.C. (2006) Temporal Changes in the Endoscopic Frequency of New Cases of Barrett’s Esophagus in an Australian Health Region. The American Journal of Gastroenterology, 101, 1178-1182.
[15] Krishnan, K., Ruffin IV, M.T. and Brenner, D.E. (2000) Chemoprevention for Colorectal Cancer. Critical Reviews in Oncology/Hematology, 33, 199-219.
[16] Shiff, J.S. and Rigas, B. (1997) Nonsteroidal Anti-Inflammatory Drugs and Colorectal Cancer: Evolving Concepts of Their Chemopreventive Actions. Gastroenterology, 113, 1992-1998.
[17] Shiff, J.S. and Rigas, B. (1999) The Role of Cyclooxygenase Inhibition in the Antineoplastic Effects of Nonsteroidal Anti-Inflammatory Drugs. The Journal of Experimental Medicine, 190, 445-450.
[18] Hardman, J.G., Limbert, L.E., Molinoff, P.B., Ruddon, R.W. and Gilman, A.G., Eds. (1996) Goodman and Gilman’s the Pharmacological Basis of Therapeutics. 9th Edition, McGraw-Hill, Inc., New York.
[19] Bjorkman, D.J. (1999) Current Status of Nonsteroidal Anti-Inflammatory Drug (NSAID) Use in the United States: Risk Factors and Frequency of Complications. American Journal of Medicine, 107, 3S-8S.
[20] Del Soldato, P., Sorrentino, R. and Pinto, A. (1999) NO-Aspirins: A Class of New Anti-Inflammatory and Antithrombotic Agents. Trends in Pharmacological Sciences, 20, 319-323.
[21] Wolfe, M.M. (1998) Future Trends in the Development of Safer Nonsteroidal Anti-Inflammatory Drugs. American Journal of Medicine, 105, 44S-52S.
[22] Fiorucci, S., Antonelli, E., Santucci, L., Morelli, O., Miglietti, M., Federici, B., Mannucci, R., Del Soldato, P. and Morelli, A. (1999) Gastrointestinal Safety of Nitric Oxide-Derived Aspirin Is Related to Inhibition of ICE-Like Cysteine Proteases in Rats. Gastroenterology, 116, 1089-1106.
[23] Qiao, L., Hanif, R., Sphicas, E., Shiff, S.J. and Rigas, B. (1998) Effect of Aspirin on Induction of Apoptosis in HT-29 Human Colon Adenocarcinoma Cells. Biochemical Pharmacology, 55, 53-64.
[24] Shiff, S.J., Koutsos, M.I., Qiao, L. and Rigas, B. (1996) Nonsteroidal Anti-Inflammatory Drugs Inhibit the Proliferation of Colon Adenocarcinoma Cells: Effects on Cell Cycle and Apoptosis. Experimental Cell Research, 222, 179-188.
[25] Hanif, R., Feng, J., Shiff, S.J., Koutsos, M.I., Staiano-Coico, L. and Rigas, B. (1996) NSAIDs Inhibit the Growth of Colon Cancer Cells by a Prostaglandin-Independent Pathway. Biochemical Pharmacology, 52, 237-245.
[26] Rigas, B. and Shiff, S.J. (2000) Is an Effect on Cyclooxygenase Required for the Chemopreventive Effect of NSAIDs in Colon Cancer? A Model Reconciling the Current Contradiction. Medical Hypotheses, 54, 210-215.
[27] Bakm, A.W., McKnight, W., Li, P., Del Soldato, P., Calignano, A., Cirino, G. and Wallace, J.L. (1998) Cyclooxygenase-Independent Chemoprevention with an Aspirin Derivative in a Rat Model of Colonic Adenocarcinoma. Life Sciences, 62, 367-373.
[28] Garcia-Rodriguez, L.A. and Huerta-Alvarez, C. (2001) Reduced Risk of Colorectal Cancer among Long-Term Users of Aspirin and Non-Aspirin Nonsteroidal Anti-Inflammatory Drugs. Epidemiology, 12, 88-93.
[29] Rosenberg, L., Palmer, J.R., Zauber, A.G., Warshauer, M.E., Stolley, P.D. and Shapiro, S. (1991) A Hypothesis: Nonsteroidal Anti-Inflammatory Drugs Reduce the Incidence of Large Bowel Cancer. Journal of the National Cancer Institute, 83, 355-358.
[30] Rosenberg, L., Louik, C. and Shapiro, S. (1998) Nonsteroidal Anti-Inflammatory Drug Use and Reduced Risk of Large Bowel Carcinoma. Cancer, 82, 2326-2333.<2326::AID-CNCR5>3.0.CO;2-Q
[31] Giovannucci, E., Rim, E.B., Stampfer, M.J., Colditz, G.A., Ascherio, A. and Willett, W.C. (1994) Aspirin Use and the Risk of Colorectal Cancer and Adenoma in Male Health Professionals. Annals of Internal Medicine, 121, 241-246.
[32] Giovannucci, E., Egan, K., Hunter, D.J., Stampfer, M.J., Colditz, G.A., Ascherio, A., Willett, W.C. and Speizer, F.E. (1995) Aspirin and the Risk of Colorectal Cancer in Women. The New England Journal of Medicine, 333, 609-614.
[33] Berkel, H.J., Holcombe, R.F., Middlebrooks, M. and Kannan, K. (1996) Nonsteroidal Anti-Inflammatory Drugs and Colorectal Cancer. Epidemiologic Reviews, 18, 205-217.
[34] Thun, M.J., Namboodiri, M.M. and Heath Jr., C.W. (1991) Aspirin Use and Reduced Risk of Fatal Colon Cancer. The New England Journal of Medicine, 325, 1593-1596.
[35] Muscat, J.E., Stellman, S.D. and Wynder, E.L. (1994) Nonsteroidal Anti-Inflammatory Drugs and Colorectal Cancer. Cancer, 74, 1847-1854.
[36] Pollard, M. and Luckert, P.H. (1980) Indomethacin Treatment of Rats with Dimethylhydrazine-Induced Intestinal Tumors. Cancer Treatment Reviews, 64, 1323-1327.
[37] Pollard, M. and Luckert, P.H. (1984) Effect of Piroxicam on Primary Intestinal Tumors Induced in Rats by N-Methylnitrosourea. Cancer Letters, 25, 117-121.
[38] Metzger, U., Meier, J., Uhlshmid, G. and Weihe, H. (1984) Influence of Various Prostaglandin Synthesis Inhibitors on DMH-Induced Rat Colon Cancer. Diseases of the Colon & Rectum, 27, 366-369.
[39] Reddy, B.S., Maruyama, H. and Kelloff, G. (1987) Dose-Related Inhibition of Dietary Piroxicam, a Nonsteroidal Anti-Inflammatory Drug, during Different Stages of Rat Colon Tumor Development. Cancer Research, 47, 5340-5346.
[40] Reddy, B.S., Nayini, J., Tokumo, K., Rigotty, J., Zang, E. and Kelloff, G. (1990) Chemoprevention of Colon Carcinogenesis by Concurrent Administration of Piroxicam, a Nonsteroidal Anti-Inflammatory Drug with D,L-a-diftuoromethylor-nithine, an Ornithine Decarboxylase Inhibitor, in Diet. Cancer Research, 50, 2562-2568.
[41] Rubio, C.A. (1984) Antitumoral Activity of Indomethacin on Experimental Esophageal Tumors. Journal of the National Cancer Institute, 72, 705-707.
[42] Takahashi, M., Furukawa, F., Toyoda, K., Sato, H., Hasegawa, R., Imaida, K. and Hayashi, Y. (1990) Effects of Various Prostaglandin Synthesis Inhibitors on Pancreatic carcinogenesis in Hamsters after Initiation with N-Nitrosobis(2-oxopropyl)amine. Carcinogenesis, 11, 393-395.
[43] Tanaka, T., Kojima, T., Okumura, A., Sugie, S. and Mori, H. (1993) Inhibitory Effect of the Non-Steroidal Anti-Inflammatory Drugs, Indomethacin and Piroxicam on 2-Acetylaminofluorene-Induced Hepatocarcinogenesis in Male ACI/N Rats. Cancer Letters, 68, 111-118.
[44] Jalbert, G. and Castonguay, A. (1992) Effects of NSAIDs on NNK-Induced Pulmonary and Gastric Tumorigenesis in A/J Mice. Cancer Letters, 66, 21-28.
[45] Thun, M.S., Namboodiri, M.M., Calle, E.E., Flanders, M.D. and Heath Jr., C.W. (1993) Aspirin Use and Risk of Fatal Cancer. Cancer Letters, 53, 1322-1327.
[46] Gridley, G., McLaughlin, J.K., Ekbom, A., Klareskog, L., Adami, H.O., Hacker, D.G., Hoover, R. and Fraumeni, J.F. (1993) Incidence of Cancer among Patients with Rheumatoid Arthritis. Journal of the National Cancer Institute, 85, 307-311.
[47] Funkhouser, E.M. and Sharp, G.B. (1995) Aspirin and Reduced Risk of Esophageal Carcinoma. Cancer, 76, 1116-1119.<1116::AID-CNCR2820760703>3.0.CO;2-I
[48] Farrow, D.C., Vaughan, T.L., Hansten, P.D., Stanford, J.L., Risch, H.A., Gammon, M.D., Chow, W.H., Dubrow, R., Ahsan, H., Mayne, S.T., Schoenberg, J.B., West, A.B., Rotterdam, H., Fraumeni Jr., J.F. and Blot, W.J. (1998) Use of Aspirin and Other Nonsteroidal Anti-Inflammatory Drugs and Risk of Esophageal and Gastric Cancer. Cancer Epidemiology, Biomarkers & Prevention, 7, 97-102.
[49] Shapiro, S. (1982) Case-Control Surveillance. In: Strom, B.L., Ed., Pharmacoepidemiology, 2nd Edition, John Wiley and Sons, Chichester, 301-322.
[50] Schreinemachers, D.M. and Everson, R.B. (1994) Aspirin Use and Lung, Colon, and Breast Cancer Incidence in a Prospective Study. Epidemiology, 5, 138-146.
[51] World Health Organization (2012) World Health Statistics 2012.
[52] Flegal, K.M., Carroll, M.D., Kit, B.K. and Ogden, C.L. (2012) Prevalence of Obesity and Trends in the Distribution of Body Mass Index among US Adults, 1999-2010. The Journal of the American Medical Association, 307, 491-497.
[53] Calle, E.E., Rodriguez, C., Walker-Thurmond, K. and Thun, M.J. (2003) Overweight, Obesity, and Mortality from Cancer in a Prospectively Studied Cohort of US Adults. The New England Journal of Medicine, 348, 1625-1638.

comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.